Sandoz Group AG (SDZ.SW)
| Previous Close | 40.28 |
| Open | 40.15 |
| Bid | 40.43 x N/A |
| Ask | 40.44 x N/A |
| Day's Range | 40.08 - 40.56 |
| 52 Week Range | 25.01 - 41.16 |
| Volume | |
| Avg. Volume | 957,783 |
| Market Cap | 17.382B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.02 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.45 (1.12%) |
| Ex-Dividend Date | May 03, 2024 |
| 1y Target Est | 47.59 |
GlobeNewswireSandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio
MEDIA RELEASE Afqlir® (aflibercept) approved to treat various retinal diseases, including neovascular age-related macular degeneration (nAMD)One of several biosimilar value drivers for SandozSandoz remains committed to accelerating patient access by strengthening its biosimilar portfolio, reinforcing global and European leadership Basel, November 15, 2024 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, today announced that the European Commission (EC) has g
- GlobeNewswire
Sandoz reports third-quarter and nine-month 2024 sales
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Strong third-quarter biosimilars growth of 37% in constant currencies from existing portfolio and recent launchesGenerics growth acceleration driven by EuropeThird-quarter net sales¹ of USD 2.6 billion, up 12% in constant currencies (up 11% in USD)Nine-month net sales of USD 7.6 billion, up 9% in constant currencies (up 8% in USD)Net sales growth guidance increased to high-single digit in constant currencies (
